Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M.J. Al

Ce4 - Cost-Effectiveness Analysis of First-Line Osimertinib in Patients With Egfr Mutation-Positive Non-Small Cell Lung Cancer

Value in Health

Occupational Health

English

Related publications

Cost‐Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR‐Mutation‐Positive Non‐Small Cell Lung Cancer

Cancer Research

English

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation

Cancer Research

English

P043 Cost-Effectiveness Analysis of Different Sequences of Osimertinib Administration for EGFR-Mutated Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Clinical Analysis of EGFR‐ Positive Non‐small Cell Lung Cancer Patients Treated With First‐line Afatinib: A Nagano Lung Cancer Research Group

Thoracic Cancer

Respiratory Medicine

English

P2.13-42 Osimertinib Treatment for Patients With EGFR Exon 20 Insertion Positive Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-77 Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation From Circulating Tumor DNA

Journal of Thoracic Oncology

Respiratory Medicine

English

Cost-Effectiveness of First-Line Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer Unsuitable for Chemotherapy

English

P2.01-29 Economic Analysis of Osimertinib in Previously Untreated EGFR-Positive Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Pcn44 - First-Line Treatment Efficacy in Egfr-Positive Non-Small Cell Lung Cancer: A Network Meta-Analysis

Value in Health

Occupational Health

English